文献速递免疫规划卫生政策与健康促进

健康个体接种mRNA疫苗后的纵向蛋白质组与自身抗体特征

Longitudinal proteomic and autoantibody signatures after mRNA vaccination in healthy individuals.
PubMed 文献 · Vaccine · 2025-11-27

研究分析了114名健康参与者接种SARS-CoV-2 mRNA疫苗后6个时间点的120份配对血浆样本,发现针对刺突蛋白RBD、S1、S2的IgG抗体可持续长达24周,且未检测到核衣壳或膜抗体。蛋白质组学显示214种蛋白显著改变,以16-24周为主,包括补体C1复合物上调及SERPING1下调,血小板相关蛋白变化极小;自身抗体谱总体稳定,仅部分白细胞介素自身抗体later time points轻度升高。结论认为mRNA疫苗免疫原性持久、安全性良好,表现为刺突特异性抗体持久、补体激活晚发及自身抗体诱导有限。

要点

  • 接种mRNA疫苗后刺突蛋白RBD、S1、S2的IgG抗体可持续至24周。
  • 未检测到核衣壳或膜抗体,提示无既往感染。
  • 16-24周可见补体C1复合物上调及SERPING1下调,血小板相关蛋白变化极小。

核心结论

  • 整合血浆蛋白质组学与自身抗体谱分析显示,SARS-CoV-2 mRNA疫苗具有持久的免疫原性和安全性,特征为刺突特异性抗体应答持久、补体激活晚发及自身抗体诱导有限。

研究设计与样本

  • 研究分析了114名健康参与者的120份配对血浆样本,采集时间点为接种前、第1剂后3天和7-21天、第2剂后7-21天以及第2剂后8周、16周和24周。
  • 采用多重平台评估针对SARS-CoV-2结构蛋白的IgG抗体应答和自身抗体谱,并用质谱法定量血浆蛋白质组变化。

主要发现

  • 针对刺突蛋白区域(RBD、S1、S2)的IgG抗体产生可持续长达24周的应答,未检测到核衣壳或膜抗体,证实无既往感染。
  • 年轻参与者(<45岁)呈现更强的应答,未观察到显著性别差异。
  • 蛋白质组学鉴定出342种蛋白,其中214种蛋白显著改变,主要发生在16-24周。
  • 关键变化包括C1复合物蛋白(C1R、C1QC、C1S)上调及C1抑制剂SERPING1下调,提示补体激活;血小板相关蛋白变化极小,提示血栓风险有限。
  • 改变的蛋白富集于碳水化合物代谢、辅因子/维生素代谢和甲状腺激素通路;自身抗体谱显示大多数自身抗原应答稳定,later time points几种白细胞介素特异性自身抗体(包括IL-1B)轻度升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Longitudinal analysis of the circulating proteome after SARS-CoV-2 mRNA vaccination provides insights into immune adaptation, optimizing vaccination strategies, and understanding long-term molecular effects. METHODS: We analyzed 120 paired plasma samples from 114 healthy participants at six time points: pre-vaccination, 3 days and 7-21 days post-dose 1, 7-21 days post-dose 2, and at 8-, 16-, and 24-weeks post-dose 2. IgG antibody responses to SARS-CoV-2 structural proteins and autoantibody profiles were assessed using a multiplex platform, and plasma proteome changes were quantified by mass spectrometry. RESULTS: IgG antibodies against spike protein regions (RBD, S1, S2) produced sustained responses for up to 24 weeks, with no detection of nucleocapsid or membrane antibodies, confirming that there was no prior infection. Younger participants (<45 years) presented stronger responses, with no significant sex differences. Proteomics identified 342 proteins, of which 214 proteins were significantly altered, predominantly at 16-24 weeks. Key changes included upregulation of C1 complex proteins (C1R, C1QC, C1S) and downregulations of the C1 inhibitor SERPING1, indicating complement activation. Platelet-associated proteins showed minimal changes, suggesting a limited thrombosis risk. Altered proteins were enriched in carbohydrate metabolism, cofactors/vitamin metabolism, and thyroid hormone pathways. Autoantibody profiling showed stable responses for most self-antigens, with modest increased in several interleukin specific autoantibodies, including IL-1B, at later time points. CONCLUSIONS: Integrated plasma proteomics and autoantibody profiling demonstrated sustained immunogenicity and safety of SARS-CoV-2 mRNA vaccines, characterized by durable spike-specific antibody responses, late-onset complement activation, and limited autoantibody induction. These findings enhance our understanding of vaccine-induced immunity and inform long-term monitoring and optimization of mRNA vaccine strategies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chazarin B, Bhat AS, Sundararaman N, et al. Longitudinal proteomic and autoantibody signatures after mRNA vaccination in healthy individuals. Vaccine. 2025. PMID: 41313893. doi:10.1016/j.vaccine.2025.127888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。